Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.
作者信息
Klug Lillian R, Corless Christopher L, Heinrich Michael C
机构信息
Oregon Health & Science University, Knight Cancer Institute, Portland, OR.
Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR.
出版信息
J Clin Oncol. 2021 May 20;39(15):1674-1686. doi: 10.1200/JCO.20.03245. Epub 2021 Apr 2.
Abstract
摘要
相似文献
1
Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.
J Clin Oncol. 2021 May 20;39(15):1674-1686. doi: 10.1200/JCO.20.03245. Epub 2021 Apr 2.
2
The direct association of the multiple PDZ domain containing proteins (MUPP-1) with the human c-Kit C-terminus is regulated by tyrosine kinase activity.
FEBS Lett. 2000 Sep 29;482(1-2):54-8. doi: 10.1016/s0014-5793(00)02036-6.
3
JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor.
Blood. 1996 May 1;87(9):3688-93.
4
The reproductive activity in the testis of Podarcis s. sicula involves D-aspartic acid: a study on c-kit receptor protein, tyrosine kinase activity and PCNA protein during annual sexual cycle.
Gen Comp Endocrinol. 2009 May;161(3):373-83. doi: 10.1016/j.ygcen.2009.02.002. Epub 2009 Feb 12.
5
The desmoid tumor: still an enigma.
J Surg Res. 2012 Mar;173(1):46-8. doi: 10.1016/j.jss.2011.01.039. Epub 2011 Feb 20.
6
Significance of tyrosine kinases in cancer: overview.
Eur J Cancer. 2002 Sep;38 Suppl 5:S2. doi: 10.1016/s0959-8049(02)80596-2.
7
Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
Biochem Biophys Res Commun. 2005 Nov 11;337(1):1-13. doi: 10.1016/j.bbrc.2005.08.055.
8
Expression of protein tyrosine kinases in head and neck squamous cell carcinomas.
Am J Clin Pathol. 2006 Oct;126(4):618.
9
Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C.
J Biol Chem. 1994 Aug 26;269(34):21793-802.
10
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
Blood. 2000 Aug 1;96(3):925-32.
引用本文的文献
1
Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics.
Ther Adv Hematol. 2025 Apr 16;16:20406207251330064. doi: 10.1177/20406207251330064. eCollection 2025.
2
[The efficacy and safety of avapritinib in the treatment of molecular biologically positive core binding factor-acute myeloid leukemia with KIT mutation after allogeneic hematopoietic stem cell transplantation].
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):761-766. doi: 10.3760/cma.j.cn121090-20240129-00043.
3
Levels of circulating tumor DNA correlate with tumor volume in gastro-intestinal stromal tumors: an exploratory long-term follow-up study.
Mol Oncol. 2024 Nov;18(11):2658-2667. doi: 10.1002/1878-0261.13644. Epub 2024 May 24.
4
If it's a target, it's a pan-cancer target: Tissue is not the issue.
Cancer Treat Rev. 2024 Apr;125:102721. doi: 10.1016/j.ctrv.2024.102721. Epub 2024 Mar 21.
5
Individualized Dosing Patterns in the Treatment of Older Patients with Gastrointestinal Stromal Tumors: Results of a Registry-Based Observational National Cohort Study Including 871 Patients.
Drugs Aging. 2024 Feb;41(2):165-176. doi: 10.1007/s40266-023-01084-8. Epub 2023 Dec 20.
6
c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights.
Onco Targets Ther. 2023 Sep 27;16:785-799. doi: 10.2147/OTT.S404648. eCollection 2023.
7
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
Int J Mol Sci. 2022 Apr 23;23(9):4694. doi: 10.3390/ijms23094694.
8
New treatment strategies for advanced-stage gastrointestinal stromal tumours.
Nat Rev Clin Oncol. 2022 May;19(5):328-341. doi: 10.1038/s41571-022-00606-4. Epub 2022 Feb 25.
本文引用的文献
1
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.
Cancer Discov. 2021 Jan;11(1):108-125. doi: 10.1158/2159-8290.CD-20-0487. Epub 2020 Sep 24.
2
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
J Clin Oncol. 2020 Oct 1;38(28):3294-3303. doi: 10.1200/JCO.20.00522. Epub 2020 Aug 17.
3
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Lancet Oncol. 2020 Jul;21(7):935-946. doi: 10.1016/S1470-2045(20)30269-2.
4
Ripretinib: First Approval.
Drugs. 2020 Jul;80(11):1133-1138. doi: 10.1007/s40265-020-01348-2.
5
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol. 2020 Jul;21(7):923-934. doi: 10.1016/S1470-2045(20)30168-6. Epub 2020 Jun 5.
6
Avapritinib: First Approval.
Drugs. 2020 Mar;80(4):433-439. doi: 10.1007/s40265-020-01275-2.
7
Avapritinib Approved for GIST Subgroup.
Cancer Discov. 2020 Mar;10(3):334. doi: 10.1158/2159-8290.CD-NB2020-002. Epub 2020 Jan 23.
8
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
Future Oncol. 2020 Jan;16(1):4251-4264. doi: 10.2217/fon-2019-0633. Epub 2019 Nov 22.
9
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Br J Haematol. 2019 Nov;187(4):488-501. doi: 10.1111/bjh.16092. Epub 2019 Jul 15.
10
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
Cancer Res. 2019 Aug 15;79(16):4283-4292. doi: 10.1158/0008-5472.CAN-18-3139. Epub 2019 Jul 3.
Zotero 插件